These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 16023762

  • 1. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics.
    Huether A, Höpfner M, Sutter AP, Schuppan D, Scherübl H.
    J Hepatol; 2005 Oct; 43(4):661-9. PubMed ID: 16023762
    [Abstract] [Full Text] [Related]

  • 2. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2005 Nov 25; 70(11):1568-78. PubMed ID: 16226226
    [Abstract] [Full Text] [Related]

  • 3. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherübl H.
    J Hepatol; 2004 Dec 25; 41(6):1008-16. PubMed ID: 15582135
    [Abstract] [Full Text] [Related]

  • 4. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
    Sutter AP, Höpfner M, Huether A, Maaser K, Scherübl H.
    Int J Cancer; 2006 Apr 01; 118(7):1814-22. PubMed ID: 16217753
    [Abstract] [Full Text] [Related]

  • 5. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2006 May 14; 71(10):1435-48. PubMed ID: 16530734
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2000 May 14; 6(5):2053-63. PubMed ID: 10815932
    [Abstract] [Full Text] [Related]

  • 7. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y, Poon RT, Shao W, Sun X, Chen H, Kok TW, Fan ST.
    Cancer Lett; 2007 Apr 08; 248(1):32-40. PubMed ID: 16837130
    [Abstract] [Full Text] [Related]

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 9. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
    Sutter AP, Maaser K, Grabowski P, Bradacs G, Vormbrock K, Höpfner M, Krahn A, Heine B, Stein H, Somasundaram R, Schuppan D, Zeitz M, Scherübl H.
    J Hepatol; 2004 Nov 01; 41(5):799-807. PubMed ID: 15519653
    [Abstract] [Full Text] [Related]

  • 10. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
    Saigal B, Glisson BS, Johnson FM.
    Anticancer Drugs; 2008 Jun 01; 19(5):465-75. PubMed ID: 18418213
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM.
    Cancer Res; 2005 Apr 15; 65(8):3328-35. PubMed ID: 15833866
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
    Ren W, Korchin B, Zhu QS, Wei C, Dicker A, Heymach J, Lazar A, Pollock RE, Lev D.
    Clin Cancer Res; 2008 May 01; 14(9):2785-95. PubMed ID: 18451246
    [Abstract] [Full Text] [Related]

  • 13. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, Perez-Soler R.
    Clin Cancer Res; 2005 Feb 15; 11(4):1572-8. PubMed ID: 15746062
    [Abstract] [Full Text] [Related]

  • 14. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M, Feisthammel J, Blüthner T, Tannapfel A, Kamenz T, Kluge A, Mössner J, Caca K.
    Anticancer Drugs; 2006 Aug 15; 17(7):783-95. PubMed ID: 16926628
    [Abstract] [Full Text] [Related]

  • 15. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 15; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 16. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A.
    J Cell Physiol; 2004 Oct 15; 201(1):97-105. PubMed ID: 15281092
    [Abstract] [Full Text] [Related]

  • 17. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H, Li L, Li XQ, Liu XJ, Zhen YS.
    Anticancer Drugs; 2009 Jan 15; 20(1):41-9. PubMed ID: 19342999
    [Abstract] [Full Text] [Related]

  • 18. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G.
    Cancer Res; 2007 Jul 01; 67(13):6253-62. PubMed ID: 17616683
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
    Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E.
    Clin Cancer Res; 2004 Nov 15; 10(22):7547-54. PubMed ID: 15569985
    [Abstract] [Full Text] [Related]

  • 20. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
    Sieghart W, Pinter M, Dauser B, Rohr-Udilova N, Piguet AC, Prager G, Hayden H, Dienes HP, Dufour JF, Peck-Radosavljevic M.
    J Hepatol; 2012 Sep 15; 57(3):592-9. PubMed ID: 22634341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.